Promising Results For Patients With Aggressive, Recurrent Non-Hodgkin Lymphoma Using New Oral Drug

... Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, recently presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma. ...